ArticleFrontiers in endocrinology2019
The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome.
Article in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis.BMC endocrine disorders · 2023Pooled it
- Trial
- Dysregulation of Endothelial cell markers in polycystic ovary syndrome.Scientific reports · 2026Article
- Article
- The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review.Cureus · 2025Review
- The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties.Medicina (Kaunas, Lithuania) · 2024Review
- Article
- The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome.Journal of clinical medicine · 2023Review
- Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome.Biomedicines · 2023Article
- Polycystic ovary syndrome: pathophysiology and therapeutic opportunities.BMJ medicine · 2023Review
- Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives.Biomedicines · 2022Review
- The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.Therapeutic advances in endocrinology and metabolism · 2021 · on this mapReview
- Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS.International journal of molecular sciences · 2020Review
- The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome.Endocrine connections · 2020Article
- A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome.Therapeutic advances in endocrinology and metabolism · 2020Review
- Effect of GLP-1 Receptor Agonists in the Cardiometabolic Complications in a Rat Model of Postmenopausal PCOS.Endocrinology · 2019Article
- Novel Antidiabetic Medications in Polycystic Ovary Syndrome.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.